OCUL · Ocular Therapeutix, Inc
$10.04
-0.06 (-0.59%)
At close · Aug 14
Market Cap
$2.20B
Shares
219.62M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jason Robins | Chief Financial Officer | Appointed | 2026-06-12 |
| Jason Robins | interim Chief Financial Officer | Appointed | 2026-01-23 |
| Leslie J. Williams | Class II director | Appointed | 2025-06-11 |
| Richard L. Lindstrom, M.D. | Class II director | Appointed | 2025-06-11 |
| Seung Suh Hong, Ph.D. | Class II director | Appointed | 2025-06-11 |
| Donald Notman | Chief Operating Officer | Appointed | 2024-09-03 |
| Charles Warden | Class I director | Appointed | 2024-06-14 |
| Adrienne L. Graves, Ph.D. | Class I director | Appointed | 2024-06-14 |
| Rabia Gurses Ozden, M.D. | Chief Medical Officer | Resigned | 2024-04-18 |
| Nadia Waheed, M.D. | Chief Medical Officer | Appointed | 2024-04-18 |
| Antony C. Mattessich | board of directors | Resigned | 2024-04-18 |
| Antony C. Mattessich | President and Chief Executive Officer | Resigned | 2024-04-18 |
| Pravin U. Dugel, M.D. | President and Chief Executive Officer | Appointed | 2024-04-18 |
| Adrienne L. Graves, Ph.D. | member of the Board | Appointed | 2023-07-12 |
| Jeffrey S. Heier, M.D. | Class III director | Appointed | 2023-06-16 |
| Merilee Raines | Class III director | Appointed | 2023-06-16 |
| Richard L. Lindstrom, M.D. | Class II director | Appointed | 2022-06-17 |
| Leslie J. Williams | Class II director | Appointed | 2022-06-17 |
| Seung Suh Hong, Ph.D. | Class II director | Appointed | 2022-06-17 |
| Rabia Gurses Ozden, M.D. | Chief Medical Officer | Appointed | 2022-06-08 |
Key facts
CIK
1393434
CUSIP
67576A100
13F (30d)
252 filings
247 filers
Visit website
Investor relations